Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc, the drugmaker said late on Tuesday.​

Quest Diagnostics and Haystack Oncology said Thursday that they have reached a definitive agreement for Quest to acquire Haystack for up to $450 million in cash.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Ultima Genomics and Genome Insight said on Monday that they are collaborating to develop affordable whole-genome sequencing testing for cancer patients.

The UK National Health Service said last week that it would offer genetic testing for Lynch syndrome to all patients diagnosed with bowel and endometrial cancer.

Leica Biosystems and Paige announced that they are expanding their previously announced digital pathology partnership. ​

QIAGEN announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).

On February 20, Roche Group and Zhuhai People's Hospital Medical Group formally signed a strategic cooperation agreement.

Ibex Medical Analytics has received CE mark for its pathology diagnostics platform, Galen Prostate, under the European Union’s (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR).